Gilead Sciences, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Gilead Sciences, Inc. - overview
Established
1987
Location
Foster City, CA, US
Primary Industry
Biotechnology
About
Founded in 1987 and based in California, US, Gilead Sciences, Inc. is on developing medicines for the treatment of life-threatening diseases, including HIV/AIDS, cancer, and respiratory, cardiovascular, and liver diseases. In January 1992, Gilead Sciences, Inc. raised USD 86.
25 million in an IPO, selling 5. 75 million shares. Venrock exited their stake in Gilead Sciences, Inc. As of July 2024, the company is led by CEO Daniel O'Day.
The company's portfolio includes over 25 therapies addressing critical diseases such as HIV/AIDS, viral hepatitis, oncology (Cancer), and other conditions like pulmonary arterial hypertension, and COVID-19 with Veklury (remdesivir). The product pipeline includes over 54 programs across various phases, including treatments for HIV, hepatitis B, cancer, and inflammatory diseases. The company's robust portfolio includes over 25 therapies in the United States.
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.gilead.com
Verticals
Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only
Gilead Sciences, Inc. - timeline of key events
Gilead Sciences, Inc. - financials
| Fiscal Year Ended | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 11,201,688,000 | 24,890,000,000 | 32,639,000,000 | 30,390,000,000 | 26,107,000,000 | 22,127,000,000 | 22,449,000,000 | 24,689,000,000 | 27,305,000,000 | 27,281,000,000 | - | - | - |
| % Revenue Growth (YoY) | - | 122.2% | 31.1% | (6.9%) | (14.1%) | (15.2%) | 1.5% | 10.0% | 10.6% | (0.1%) | - | - | - |
| EBITDA (USD) | 4,868,703,000 | 16,315,000,000 | 23,291,000,000 | 18,791,000,000 | 15,410,000,000 | 9,629,000,000 | 5,691,000,000 | 5,551,000,000 | 11,968,000,000 | 9,433,000,000 | - | - | - |
| Operating Income (USD) | 4,523,999,000 | 15,265,000,000 | 22,193,000,000 | 17,633,000,000 | 14,124,000,000 | 8,200,000,000 | 4,287,000,000 | 4,071,000,000 | 9,918,000,000 | 7,330,000,000 | - | - | - |
| Operating Margin | 40.4% | 61.3% | 68.0% | 58.0% | 54.1% | 37.1% | 19.1% | 16.5% | 36.3% | 26.9% | - | - | - |
| % EBITDA Margin | 43.5% | 65.5% | 71.4% | 61.8% | 59.0% | 43.5% | 25.4% | 22.5% | 43.8% | 34.6% | - | - | - |
| NET Income (USD) | 3,057,286,000 | 12,059,000,000 | 18,106,000,000 | 13,488,000,000 | 4,644,000,000 | 5,460,000,000 | 5,364,000,000 | 89,000,000 | 6,201,000,000 | 4,566,000,000 | - | - | - |
| % Net Margin | 27.3% | 48.4% | 55.5% | 44.4% | 17.8% | 24.7% | 23.9% | 0.4% | 22.7% | 16.7% | - | - | - |
Gilead Sciences, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Sale | Completed | Arcellx, Inc. | - | ||||||||
| Private Debt | Completed | Gilead Sciences, Inc. | - | ||||||||
| Trade Sale | Completed | Triangle Pharmaceuticals, Inc. | - |
Displaying 1 - 3 of 3
Gilead Sciences, Inc. - employee data
Gilead Sciences, Inc. - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| President, Chief Medical Officer & Board Member | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.